moatshark My

All holdings

Bioxcel Therapeutics

BTAIQ

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
1
In their latest 13F (Q3 2026)
See who
Value held
$1.9m
Combined value at quarter end
Last quarter
1 bought
0 sold or trimmed
Price at Q2 ’26 end
$1.41
+5.2% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

+41.4%Q3 ’25
-37.5%Q4 ’25
-16.2%Q1 ’26
+5.2%Q2 ’26
Q3 ’25: +41.4%; Q4 ’25: -37.5%; Q1 ’26: -16.2%; Q2 ’26: +5.2%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

0Q4 ’23
0Q1 ’24
0Q2 ’24
0Q3 ’24
0Q4 ’24
0Q1 ’25
1Q2 ’25
1Q3 ’25
1Q4 ’25
1Q1 ’26
1Q2 ’26
0Q3 ’26
Q4 ’23: 0; Q1 ’24: 0; Q2 ’24: 0; Q3 ’24: 0; Q4 ’24: 0; Q1 ’25: 0; Q2 ’25: 1; Q3 ’25: 1; Q4 ’25: 1; Q1 ’26: 1; Q2 ’26: 1; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Bioxcel Therapeutics.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Bioxcel Therapeutics
Oaktree Capital Management0.0%$1.9m$1.9mAdded +472%5 qtrs

Download the holders: CSV · JSON · Markdown

About the company

Sector
Health care · Pharmaceutical Preparations
Incorporated in
Delaware
Financial year ends
31 December
Shares outstanding
31m at 11 Aug 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

2017
2018
2019
2020
2021
$375k2022
$1.4m2023
$2.3m2024
$642k2025
2017: not held; 2018: not held; 2019: not held; 2020: not held; 2021: not held; 2022: $375k; 2023: $1.4m; 2024: $2.3m; 2025: $642k
Bioxcel Therapeutics revenue and net income by year
YearRevenueNet income
2025$642k−$69.9m
2024$2.3m−$59.6m
2023$1.4m−$179m
2022$375k−$166m
2021–−$107m
2020–−$82.2m
2019–−$33.0m
2018–−$19.3m
2017–−$4.5m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.